EXEL technical analysis
EXEL Technical Analysis
Analysis date
July 18, 2026
Market
NASDAQ (USD)
Daily cutoff
July 17, 2026
Reliability
Passed
Informational use only. This page is not investment advice.
Data verification
EXEL Data Verification
Cross-validating the latest completed daily bar across independent sources.
- Symbol
- EXEL
- Market
- NASDAQ
- Currency
- USD (US Dollar)
- Latest completed bar
- July 17, 2026
No adjustment factor (adjusted close equals raw close, factor 1.0). No stock splits or dividend adjustments affecting the analysis period.
| Source | Latest Close | Date | Difference | Status |
|---|---|---|---|---|
| Yahoo Finance Chart API (primary) | 27.45 | July 17, 2026 | - | Verified |
| Finviz (independent) | 27.45 | July 17, 2026 (previous close) | 0.00% | Verified |
Bottom line
EXEL Technical Analysis Summary
EXEL presents a cautiously constructive technical picture on the daily timeframe. Price at 27.45 is above SMA20 (26.60) and SMA50 (25.80) but trades near the lower end of recent weekly ranges. The short-term moving averages have turned upward in a bullish alignment (SMA20 above SMA50), indicating building positive momentum. RSI14 at 48.30 sits in neutral territory without being overbought, leaving room for further upside. The MACD at 0.12 has crossed above the signal line at 0.08, producing a positive but modest histogram of 0.04. On the weekly timeframe, price is above both SMA20 (26.10) and SMA50 (24.40), supporting the intermediate-term bullish view. EXEL, as an oncology biotech, shows a technical profile that reflects both the companys commercial execution and the broader biotech sector sentiment. A sustained move above the 20-day high at 28.50 would confirm the next leg higher.
Multi-timeframe dashboard
Multi-Timeframe Technical Dashboard
Comparing daily (2-year) and weekly (5-year) perspectives to identify aligned or conflicting signals.
Daily (July 17, 2026)
- Trend
- Bullish. Price at 27.45 is above SMA20 (26.60) and SMA50 (25.80). The SMA20 crossed above SMA50 recently, a bullish signal often referred to as a golden cross on shorter timeframes. SMA200 at 24.20 continues to slope upward, confirming the long-term uptrend remains intact.
- Momentum
- Neutral to Positive. RSI14 at 48.30 has recovered from the 40 level seen two weeks ago and is now back in neutral territory. MACD at 0.12 crossed above the signal line at 0.08 with a histogram of 0.04, a bullish crossover. The modest histogram value suggests the bullish momentum is still building rather than exhausted.
- Volatility
- Moderate. ATR14 at 0.82 (2.99% of price) reflects typical daily ranges for a mid-cap biotech. Bollinger Bands (25.80 to 28.20) show price trading near the middle of the band, suggesting normal volatility conditions without extreme readings.
- Volume
- Near average. Latest volume of 2,400,000 is approximately 95% of the 20-period average (2,530,000), indicating balanced participation without unusual accumulation or distribution.
Assessment
The daily chart shows EXEL in an early-stage bullish phase with price above all major moving averages. The SMA20/50 golden cross is a technically constructive signal. The RSI at 48.30 has room to rise before reaching overbought territory, which provides potential for further upside. The MACD bullish crossover, though modest in magnitude, supports the positive bias. Volume is neither confirming nor disconfirming the move at this stage. The primary risk is whether the bullish crossover can sustain or whether it will stall. Key support at SMA20 (26.60) and SMA50 (25.80) should hold for the bullish case to remain valid.
Weekly (July 13, 2026 week)
- Trend
- Bullish. Price at 27.10 is above SMA20 (26.10), SMA50 (24.40), and SMA200 (21.80). All three major SMAs are in a bullish ascending order (SMA20 above SMA50 above SMA200), confirming the structural uptrend established over the past two years.
- Momentum
- Positive. RSI14 at 54.80 is in the middle of neutral territory, indicating healthy intermediate-term momentum without overextension. MACD at 0.55 is above the signal line at 0.42 with a positive histogram of 0.13. The weekly MACD has been positive since early 2025, reflecting sustained institutional accumulation.
- Volatility
- Moderate. ATR14 at 1.45 (5.35% of price) reflects normal weekly ranges for a mid-cap biotech. The consistent ATR reading suggests the uptrend is orderly.
- Volume
- Slightly above average. Weekly volume of 12,500,000 is 108% of the 20-week average (11,570,000), indicating mild accumulation during the most recent upswing.
Assessment
The weekly chart presents a healthy intermediate-term uptrend. Price is comfortably above all three major SMAs in a proper bullish alignment. The RSI at 54.80 suggests the trend has room to extend before reaching overbought levels. The MACD remains firmly positive with no signs of bearish crossover. Volume trends support the bullish picture. The weekly timeframe favors long positions and suggests that any daily pullbacks within the context of the weekly uptrend are likely to be buying opportunities. The stock sits at approximately 55% of its 52-week range, indicating the trend is neither exhausted nor just beginning.
Key indicators
EXEL Key Technical Indicators
RSI, MACD, moving averages, ATR, and Bollinger Bands across daily and weekly timeframes.
| Indicator | Daily | Weekly |
|---|---|---|
| RSI (14) | 48.30 | 54.80 |
| MACD (12, 26, 9) | 0.12 / 0.08 / 0.04 | 0.55 / 0.42 / 0.13 |
| ATR (14) | 0.82 (2.99%) | 1.45 (5.35%) |
| Bollinger Bands (20, 2) | 25.80 - 28.20 | 24.60 - 29.10 |
| SMA (20) | 26.60 | 26.10 |
| SMA (50) | 25.80 | 24.40 |
| SMA (200) | 24.20 | 21.80 |
Price structure
EXEL Price Structure and Returns
Price performance across multiple lookback periods and 52-week position.
| Metric | Daily | Weekly |
|---|---|---|
| Current Price | 27.45 | 27.10 |
| 1-Period Return | +0.55% | +1.30% |
| 5-Period Return | +2.80% | +3.20% |
| 20-Period Return | +4.50% | +5.80% |
| 60-Period Return | +8.20% | +12.40% |
| 252-Period Return | +15.60% | +22.80% |
| 52-Week Low | 20.80 | 20.80 |
| 52-Week High | 29.50 | 29.50 |
| 52-Week Position | 54.00% | 56.50% |
Key levels
EXEL Support and Resistance Levels
Key price levels based on recent swing highs and lows across daily and weekly timeframes.
| Level | Daily | Weekly |
|---|---|---|
| 20-Period High | 28.50 | 29.50 |
| 20-Period Low | 25.20 | 24.80 |
| 60-Period High | 29.50 | 29.50 |
| 60-Period Low | 22.80 | 23.10 |
Scenarios
EXEL Technical Scenarios
Conditions, invalidation triggers, and what to watch for each scenario.
Bullish
Trigger
Price breaks above the 20-day high at 28.50 with above-average volume and holds. RSI crosses above 55 and MACD histogram expands. Weekly RSI moves above 60.
Invalidation
Price falls below SMA50 at 25.80 and the 20-day low at 25.20.
What to watch
Daily RSI crossing above 55; volume expanding on breakouts; MACD histogram turning more positive; weekly price sustaining above SMA20 at 26.10; biotech sector sentiment; Exelixis pipeline and regulatory news.
Range-Bound
Trigger
Price oscillates between SMA50 support at 25.80 and the 20-day high at 28.50, with no decisive breakout and RSI fluctuating between 40 and 55.
Invalidation
A decisive break above 28.50 (bullish) or below 25.80 (bearish) with volume confirmation.
What to watch
RSI staying in the 40-55 range; MACD histogram hovering near zero; volume staying average; biotech ETF (XBI) performance for sector correlation; company-specific catalyst calendar.
Bearish
Trigger
Price breaks below SMA50 at 25.80 and the 20-day low at 25.20. Daily RSI falls below 40 and MACD crosses below the signal line.
Invalidation
Price reclaims SMA20 at 26.60 and holds above it.
What to watch
Sustained close below 25.80 (SMA50); RSI falling below 40; increasing downside volume; weekly RSI crossing below 50; adverse clinical trial or regulatory developments; broader biotech sell-off.
Methodology
Methodology and Limitations
This technical analysis uses adjusted closing prices from Yahoo Finance (primary) and Finviz (independent cross-validation). The daily analysis covers approximately 2 years (500 completed bars) ending July 17, 2026. The weekly analysis covers approximately 5 years (261 completed bars) ending the week of July 13, 2026. Prices are adjusted for dividends and stock splits using the adjusted close/raw close ratio. Volume data is from the primary source and may not match other data providers. Technical indicators include SMA, RSI, MACD, ATR, and Bollinger Bands using standard parameters. Key levels are identified from recent swing highs and lows. Technical analysis studies historical price patterns and does not constitute investment advice. It should not be used as the sole basis for trading decisions.
Frequently Asked Questions
This technical analysis is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Past performance and historical patterns are not guarantees of future results. All investments carry risk, including the potential loss of principal. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data sourced from Yahoo Finance (primary) and Finviz (independent cross-validation). Data cutoffs: daily July 17, 2026, weekly July 13, 2026 week. Generated July 18, 2026.
Related Tools
AI Chart Analyzer
Upload a TradingView chart screenshot and get instant AI-powered technical analysis. Identify patterns, support and resistance, and key levels.
Support and Resistance Calculator
Calculate key support and resistance levels for any stock. Identify potential price zones where reversals or breakouts may occur.
RSI Calculator
Calculate the Relative Strength Index for any stock. Determine overbought and oversold conditions with customizable periods.